Drug Profile
Rozrolimupab
Alternative Names: Anti-RhD; Anti-Rhesus D; Anti-rhesus D immunoglobulin Gs; Anti-rhesus D polyclonal antibodies; Sym-001; Symphoglobulin-DLatest Information Update: 09 Jun 2020
Price :
$50
*
At a glance
- Originator Symphogen
- Class Immunoglobulins; Polyclonal antibodies; Recombinant proteins
- Mechanism of Action Rh-Hr blood group system inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Haemolytic disease of newborn; Idiopathic thrombocytopenic purpura
Most Recent Events
- 04 Jun 2020 Symphogen has been acquired by Servier
- 01 May 2013 Rozrolimupab is considered to be outside Symphogen's oncology focus, and its further development is dependent on identification of a global partner
- 01 May 2013 Suspended - Phase-II for Haemolytic disease of newborn in Germany (IM)